Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours

Aims: To measure vascular endothelial growth factor (VEGF-A) mRNA in a large, diverse cohort of tumours and to investigate whether VEGF-A expression is associated with markers of hypoxia, including hypoxia inducible factor 1α (HIF-1α) and carbonic anhydrase IX (CA9). Methods: The expression of VEGF-A and CA9 was assessed in 5067 fresh frozen human tissue samples and 238 cell lines by DNA microarray analysis. In addition, tissue microarrays were constructed from 388 malignancies to investigate the expression of VEGF-A and HIF-1α by in situ hybridisation and immunohistochemistry, respectively. Results: VEGF-A was significantly upregulated in primary malignancies of the breast, cervix, colon and rectum, oesophagus, head and neck, kidney, ovary, skin, urinary system, and white blood cells by DNA microarray analysis. However, VEGF-A expression only correlated with CA9 expression in renal tissues. In the tissue microarrays, HIF-1α positive cores showed a significant increase in VEGF-A expression in lung, ovary, soft tissue, and thyroid malignancies. Conclusions: The expression of VEGF-A is upregulated in a large proportion of human malignancies, and may be associated with markers of hypoxia. VEGF-A expression can be induced in the absence of hypoxia and hypoxia does not always provoke VEGF-A upregulation in tumours.

[1]  Z. Hall Cancer , 1906, The Hospital.

[2]  J. Folkman,et al.  Tumor Behavior in Isolated Perfused Organs: In Vitro Growth and Metastases of Biopsy Material in Rabbit Thyroid and Canine Intestinal Segment , 1966, Annals of surgery.

[3]  J. Folkman,et al.  Tumor growth and neovascularization: an experimental model using the rabbit cornea. , 1974, Journal of the National Cancer Institute.

[4]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[5]  J. Folkman What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[6]  P. Curtin,et al.  A 24-base-pair sequence 3' to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Winer,et al.  Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. , 1993, The Journal of clinical investigation.

[8]  M. Goldberg,et al.  Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.

[9]  S. Kourembanas,et al.  Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. , 1995, Circulation research.

[10]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Donner,et al.  Induction of Vascular Endothelial Growth Factor by Insulin-like Growth Factor 1 in Colorectal Carcinoma* , 1996, The Journal of Biological Chemistry.

[12]  Q. Duh,et al.  Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. , 1996, Surgery.

[13]  G. Semenza,et al.  Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.

[14]  N. Gillett,et al.  An Optimized Protocol for In Situ Hybridization Using PCR-Generated 33P-Labeled Riboprobes , 1996 .

[15]  K. Maeda,et al.  Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis , 1997, International journal of cancer.

[16]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[17]  Anthony J. Guidi,et al.  Vascular permeability factor (Vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast , 1997, Cancer.

[18]  N. Ferrara,et al.  Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.

[19]  W. Tilley,et al.  Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. , 1997, The Journal of urology.

[20]  A. Kaider,et al.  Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease‐free survival , 1997, International journal of cancer.

[21]  O. Vinante,et al.  Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. , 1997, Journal of the National Cancer Institute.

[22]  S. Chevalier Commentary on prostatic neovascularization and vascular endothelial growth factor. , 1997, The Journal of urology.

[23]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[24]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[25]  M. Gassmann,et al.  Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. , 1998, Genes & development.

[26]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[27]  H. Ryan,et al.  HIF-1 alpha is required for solid tumor formation and embryonic vascularization. , 1998, The EMBO journal.

[28]  N. Ferrara,et al.  Corticotropin regulates vascular endothelial growth factor expression in human fetal adrenal cortical cells. , 1998, The Journal of clinical endocrinology and metabolism.

[29]  S. Akiba,et al.  Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease , 1999, Cancer.

[30]  L. Mariani,et al.  Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. , 1999, The American journal of pathology.

[31]  M. Serio,et al.  Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. , 1999, Journal of the American Society of Nephrology : JASN.

[32]  A. Harris,et al.  Vascular endothelial growth factor platelet counts, and prognosis in renal cancer , 1999, The Lancet.

[33]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[34]  T. Sawada,et al.  Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma , 1999, Cancer.

[35]  T. Mattfeldt,et al.  Molecular mediators of tumor angiogenesis: Enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer , 1999, International journal of cancer.

[36]  K. Blennow,et al.  The Role of the Polymorphic Genes Apolipoprotein E and Methylene- tetrahydrofolate Reductase in the Development of Dementia of the Alzheimer Type , 1999, Dementia and Geriatric Cognitive Disorders.

[37]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  P H Watson,et al.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.

[39]  J. C. Lee,et al.  Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. , 2000, European journal of cancer.

[40]  L. Ellis,et al.  Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. , 2000, The oncologist.

[41]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. , 2000, The American journal of pathology.

[42]  S. Loening,et al.  Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer , 2000, The Prostate.

[43]  R. Henriksson,et al.  p53 and vascular‐endothelial‐growth‐factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma , 2000, International journal of cancer.

[44]  M. Schindl,et al.  Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. , 2000, Cancer research.

[45]  G. Semenza,et al.  Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Chien-Nan Lee,et al.  Vascular Endothelial Growth Factor and Prognosis of Cervical Carcinoma , 2000, Obstetrics and gynecology.

[47]  Y. Sugisaki,et al.  Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma , 2000, British Journal of Cancer.

[48]  Å. Borg,et al.  Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas , 2000, British Journal of Cancer.

[49]  V. Catalano,et al.  Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .

[51]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[52]  A. Harris,et al.  Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. , 2001, Cancer research.

[53]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[54]  P. O’Farrell Faculty Opinions recommendation of HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. , 2001 .

[55]  H. Moch,et al.  Tissue microarray (TMA) technology: miniaturized pathology archives for high‐throughput in situ studies , 2001, The Journal of pathology.

[56]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[57]  A. Harris,et al.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  F. Peale,et al.  Detection of novel gene expression in paraffin‐embedded tissues by isotopic in situ hybridization in tissue microarrays , 2001, The Journal of pathology.

[59]  A. Harris,et al.  Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. , 2001, Cancer research.

[60]  P. Brachet,et al.  Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. , 2001, Journal of andrology.

[61]  V. Catalano,et al.  Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  C. Cordon-Cardo,et al.  Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. , 2001, The American journal of pathology.

[63]  H. Dvorak Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  E. Scarpi,et al.  Vascular endothelial growth factor and prognosis in patients with node‐negative breast cancer , 2002, International journal of cancer.

[65]  A. Harris,et al.  Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  J. Foekens,et al.  The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy , 2002, British Journal of Cancer.

[67]  Kazuki Kobayashi,et al.  VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. , 2002, Journal of the National Cancer Institute.

[68]  K. Gatter,et al.  Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin–Reed–Sternberg cells in Hodgkin's disease , 2002, The Journal of pathology.

[69]  N. Kinukawa,et al.  Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. , 2002, Cancer letters.

[70]  G. Semenza,et al.  HIF-1 and tumor progression: pathophysiology and therapeutics. , 2002, Trends in molecular medicine.

[71]  Stephen B Fox,et al.  The angiogenic switch for vascular endothelial growth factor (VEGF)‐A, VEGF‐B, VEGF‐C, and VEGF‐D in the adenoma–carcinoma sequence during colorectal cancer progression , 2003, The Journal of pathology.

[72]  Yoav Benjamini,et al.  Identifying differentially expressed genes using false discovery rate controlling procedures , 2003, Bioinform..

[73]  F. Peale,et al.  Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization , 2003, The Journal of pathology.